Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Absorbed dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Absorbed dose. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-000369-54 Sponsor Protocol Number: 60725 Start Date*: 2018-06-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Intra-arterial Lutetium-177- dotatate for treatment of patients with neuroendocrine tumor liver metastases
    Medical condition: Patients with neuro-endocrine tumors with liver metastases with an indication for treatment with lutetium-177-dotatate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001907-33 Sponsor Protocol Number: S2472 Start Date*: 2022-07-21
    Sponsor Name:Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation
    Full Title: An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere™ followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere™ Alon...
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2018-002262-39 Sponsor Protocol Number: 131I-IPA-TLX-101-001 Start Date*: 2018-10-24
    Sponsor Name:TELIX International Pty Ltd
    Full Title: A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I...
    Medical condition: 2nd line therapy of recurrent GBM (Glioblastoma multiforme), scheduled for repeat XRT.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003713-33 Sponsor Protocol Number: 70903 Start Date*: 2020-03-02
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: Diagnostic accuracy of neuroblastoma patient imaging with [18F]-mFBG PET-CT compared to [123]I-mIBG scanning
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002089-13 Sponsor Protocol Number: NB 2006 xx Start Date*: 2006-05-26
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: International Phase II Studies of 131I-mIBG in combination with topotecan and peripheral blood stem cell rescue for (A) primary resistant high risk neuroblastoma and (B) relapsed stage 4 neuroblast...
    Medical condition: Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001811-16 Sponsor Protocol Number: PS21GAP Start Date*: 2022-12-19
    Sponsor Name:Princess Maxima Center for pediatric oncology
    Full Title: 68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002053-38 Sponsor Protocol Number: MITIGATE-NeoBOMB1 Start Date*: 2016-11-30
    Sponsor Name:Medical University Innsbruck
    Full Title: A Phase I/IIa study to evaluate safety, biodistribution, dosimetry and preliminary diagnostic performance of 68Ga-NeoBOMB1 in patients with advanced TKI-treated GIST using positron-emission tomogra...
    Medical condition: Gastrointestinal stromal tumours previously or currently under TKI-treatment including at least 50% TKI-resistant patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000898-23 Sponsor Protocol Number: 2019/KEP/218 Start Date*: 2019-08-01
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: Pharmacokinetics of intramuscular tranexamic acid in trauma patients: a clinical trial
    Medical condition: Traumatic haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10053476 Traumatic haemorrhage PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001306-30 Sponsor Protocol Number: PROICM2021-04REL Start Date*: 2021-09-13
    Sponsor Name:Institut Régional du Cancer de Montpellier
    Full Title: A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine ...
    Medical condition: Patients with new progression of intestinal well-differentiated neuroendocrine tumor.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002951-39 Sponsor Protocol Number: CAAA601A32201 Start Date*: Information not available in EudraCT
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheoc...
    Medical condition: somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034876 Pheochromocytoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073860 Paraganglioma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Trial now transitioned) PT (Prematurely Ended) PL (Trial now transitioned) BE (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001897-13 Sponsor Protocol Number: ITM-LET-01 Start Date*: 2017-08-22
    Sponsor Name:ITM Solucin GmbH
    Full Title: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to tar...
    Medical condition: Patients with inoperable, progressive, somatostatin receptor-positive(SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004727-37 Sponsor Protocol Number: CAAA603A12101 Start Date*: 2019-02-18
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with...
    Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002112-26 Sponsor Protocol Number: 139B7 Start Date*: 2007-05-21
    Sponsor Name:YORK Pharma GmbH
    Full Title: Open, single-arm phase-III study to investigate the percutaneous absorption of abafungin after topical dermal application of Abafungin cream 1.0 % (YORK Pharma GmbH) in 20 patients with tinea pedis...
    Medical condition: Tinea pedis interdigital
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002867-41 Sponsor Protocol Number: OPS-C-001/D-FR-01072-001 Start Date*: 2015-12-10
    Sponsor Name:Ipsen Pharma
    Full Title: An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positi...
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002530-11 Sponsor Protocol Number: AFB-100 Start Date*: 2007-09-21
    Sponsor Name:Affibody AB
    Full Title: An exploratory study to assess the distribution of 111In-ABY-002 tracer uptake for SPECT imaging in subjects with metastatic HER2-positive breast cancer
    Medical condition: Female subjects having metastatic breast cancer with verified HER2 positive status (DAKO's HerceptTest) in the original primary tumor or one of the current metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2005-004176-21 Sponsor Protocol Number: CMC-P005 Start Date*: 2007-10-01
    Sponsor Name:CMC Contrast AB c/o Öresund Health Care Management
    Full Title: Evaluation of the diagnostic efficacy of CMC-001 (MnCl2 tetrahydrate) in MR cholangiography in patients with suspected liver lesions. A randomised, parallel group, open-label Phase II trial.
    Medical condition: Liver lesions. CMC-001 is an orally administered contrast medium containing manganese (Mn) as the active imaging substance. Manganese is absorbed by the healthy parts of the liver and will thus cre...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014694-40 Sponsor Protocol Number: SSAT033 Start Date*: 2009-11-11
    Sponsor Name:
    Full Title: A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containi...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004813-15 Sponsor Protocol Number: VERSPLASMA Start Date*: 2021-03-19
    Sponsor Name:AZ Turnhout
    Full Title: Serum concentrations of ropivacaine after unilateral pectoral nerve block type II (Pecs II) in breast cancer surgery
    Medical condition: The aim of this study is to quantify peak and mean venous serum concentrations of ropivacaine after ultrasound guided Pecs II block with 2.5mg/kg ropivacaine diluted to 30ml.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002211-11 Sponsor Protocol Number: MIP-IB12 Start Date*: 2008-02-13
    Sponsor Name:Molecular Insight Pharmaceuticals, Inc
    Full Title: A PHASE I-II STUDY EVALUATING THE MAXIMUM TOLERATED DOSE, DOSIMETRY, SAFETY, AND EFFICACY OF ULTRATRACE™ IOBENGUANE I 131 IN PATIENTS WITH MALIGNANT PHEOCHROMOCYTOMA/PARAGANGLIOMA
    Medical condition: MALIGNANT PHEOCHROMOCYTOMA/PARAGANGLIOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034876 Pheochromocytoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002996-36 Sponsor Protocol Number: 15TETE04 Start Date*: 2021-06-23
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing som...
    Medical condition: Recurrent or refractory neuroblastoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 08:04:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA